News Sentiment

MSLE sentiment intelligence

Satellos Bioscience Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 70 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.79 Week of 10 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 63

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+31.9% over one week, +70.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Price to book forward of Satellos Bioscience Inc – SWB:0IT

Market Reaction

Price moving ahead of tone

70/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 31.9% Price confirming higher
Trend fit Trend inactive 70.3% over four weeks
Fair value 21.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 42
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 63
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
Market source 8
TradingView 6
Streetwise Reports 4
MT Newswires 4
GlobeNewswire 3
simplywall.st 3
Moomoo 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 18
Regulatory and legal 5
Analyst action 3
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 70
TradingView Direct company coverage

Price to book forward of Satellos Bioscience Inc – SWB:0IT

This article provides financial information for Satellos Bioscience Inc (SWB:0IT), specifically its price to book forward value. The data is available on TradingView, which aggregates market data from ICE Data Services and reference data from FactSet. The company is listed on the

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 05:40
Source
TradingView
Streetwise Reports Direct company coverage

Biotech With Muscle Disease Drug Uncovers Results in Trial Data

Satellos Bioscience Inc. released promising six-month interim data from its TRAILHEAD study for SAT-3247, an investigational drug for Duchenne muscular dystrophy (DMD). The drug showed reduced muscle fat, increased effort, and stable strength in adult participants, leading analys

Tone
Positive 71/100
Event
Regulatory and legal
Published
11 Jul 2026 08:12
Source
Streetwise Reports
TradingView Direct company coverage

Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update

Satellos Bioscience announced promising interim six-month data for its Duchenne muscular dystrophy (DMD) drug, SAT-3247, from the ongoing TRAILHEAD study involving adult participants. The results indicate encouraging safety and efficacy signals, including improvements in muscle f

Tone
Positive 72/100
Event
Earnings
Published
11 Jul 2026 07:10
Source
TradingView
FinancialContent Direct company coverage

Satellos Bioscience Inc. - Common Stock (MSLE) Stock Price, News, Quote & History

Satellos Bioscience Inc. (MSLE) stock is trading at $9.79, up 3.71%. Recent news highlights promising early data for its DMD drug SAT-3247 from the TRAILHEAD study and upcoming presentations at medical and investor conferences. The company also recently completed a US$57.2 millio

Tone
Positive 70/100
Event
Market update
Published
11 Jul 2026 01:40
Source
FinancialContent
Streetwise Reports Direct company coverage

Satellos Bioscience Delivers Promising DMD Data With Fast Track Win

Satellos Bioscience reported promising six-month data from its TRAILHEAD study for SAT-3247 in adult Duchenne muscular dystrophy (DMD) patients, showing muscle fat reduction and improved function. The company also secured FDA Fast Track designation for SAT-3247, which is an oral

Tone
Positive 76/100
Event
Market update
Published
10 Jul 2026 16:40
Source
Streetwise Reports
Investing.com Direct company coverage

Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data

H.C. Wainwright has raised its price target for Satellos Bioscience Inc. (NASDAQ:MSLE) to $18 from $11, while maintaining a Buy rating, following positive interim trial results for its Duchenne muscular dystrophy drug, SAT-3247. The stock saw a 24% increase last week and a 59% ye

Tone
Positive 74/100
Event
Analyst action
Published
10 Jul 2026 07:10
Source
Investing.com
MarketBeat Direct company coverage

HC Wainwright Forecasts Strong Price Appreciation for Satellos Bioscience (NASDAQ:MSLE) Stock

HC Wainwright has increased its price target for Satellos Bioscience (NASDAQ:MSLE) to $18 from $11, maintaining a "buy" rating and suggesting a 100% upside. Despite a recent earnings per share miss, the consensus among analysts is a "Moderate Buy" with an average target price of

Tone
Positive 72/100
Event
Analyst action
Published
09 Jul 2026 12:40
Source
MarketBeat
The Clinical Trial Vanguard Direct company coverage

Satellos’ SAT-3247 Shows Muscle Fat Reduction in DMD Adults at Six Months

Satellos Bioscience's drug candidate, SAT-3247, has shown promising interim results in its TRAILHEAD study for adult Duchenne muscular dystrophy (DMD) patients. All four participants, aged 21 to 28, experienced a decline in biceps brachii fat fraction, increased upper limb effort

Tone
Positive 70/100
Event
Earnings
Published
09 Jul 2026 06:40
Source
The Clinical Trial Vanguard
Yahoo! Finance Canada Direct company coverage

Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247

Satellos Bioscience announced positive six-month interim data from its TRAILHEAD study for SAT-3247 in adults with Duchenne muscular dystrophy (DMD). The study showed reduced muscle fat fraction, increased upper limb effort, stable strength, lower creatine kinase levels, and a fa

Tone
Positive 75/100
Event
Market update
Published
09 Jul 2026 06:11
Source
Yahoo! Finance Canada
Market source Direct company coverage

Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence

Satellos Bioscience released positive six-month interim data from its TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy (DMD). The drug candidate showed improvements in muscle composition and upper limb activity, maintained stable strength, and continued to demonstrate

Tone
Positive 74/100
Event
Market update
Published
08 Jul 2026 20:12
Source
Market source
Moomoo Direct company coverage

Satellos Bioscience's Share Rise After SAT-3247 Shows Positive Results for Duchenne MD

Satellos Bioscience experienced a surge in its share price following positive preclinical results for its investigational drug, SAT-3247, in treating Duchenne muscular dystrophy (DMD). The study demonstrated that SAT-3247 effectively promoted muscle regeneration and increased mus

Tone
Neutral 50/100
Event
Regulatory and legal
Published
08 Jul 2026 15:40
Source
Moomoo
grafa.com Direct company coverage

Satellos reports positive TRAILHEAD data for DMD drug

Satellos Bioscience announced positive six-month interim data from its TRAILHEAD study for Duchenne muscular dystrophy drug SAT-3247. Adult patients showed a mean muscle fat fraction reduction and improvements in upper limb maximum effort and creatine kinase levels. The drug main

Tone
Positive 90/100
Event
Market update
Published
08 Jul 2026 14:40
Source
grafa.com
Stock Titan Direct company coverage

[6-K] Satellos Bioscience Inc. Current Report (Foreign Issuer) | MSLE SEC Filing - Form 6-K

Satellos Bioscience Inc. reported positive six-month interim data from its TRAILHEAD Phase 2 study of SAT-3247 in adults with Duchenne muscular dystrophy (DMD), showing reduced muscle fat fraction, increased total effort, stable strength, and a favorable safety profile. The compa

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 10:39
Source
Stock Titan
Stock Titan Direct company coverage

If You Invested $1,000 in Satellos Bioscience Inc (MSCLF)

This article analyzes the historical performance of Satellos Bioscience Inc. (MSCLF) stock, detailing how a $1,000 investment would have grown over 1, 5, and 10 years. It also provides an overview of the company, a clinical-stage biotechnology firm focused on restoring muscle rep

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 07:08
Source
Stock Titan
Streetwise Reports Direct company coverage

Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market

Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) has received FDA Fast Track designation for its Duchenne muscular dystrophy treatment, SAT-3247, aiming to accelerate its development. This designation, coupled with existing Orphan Drug and Rare Pediatric Disease designations, pos

Tone
Positive 74/100
Event
Market update
Published
03 Jul 2026 09:11
Source
Streetwise Reports
Streetwise Reports Direct company coverage

Satellos Bioscience Fast Track Win Fuels DMD Hopes

Satellos Bioscience's SAT-3247, a treatment for Duchenne muscular dystrophy (DMD), has received FDA Fast Track designation, aiming to accelerate its regulatory review. The DMD market is projected for significant growth, reaching US$62.13 billion by 2030, presenting a substantial

Tone
Positive 81/100
Event
Regulatory and legal
Published
03 Jul 2026 00:09
Source
Streetwise Reports
GlobeNewswire Direct company coverage

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

Satellos Bioscience Inc. announced that the FDA has granted Fast Track designation to SAT-3247 for Duchenne muscular dystrophy, adding to its Orphan Drug and Rare Pediatric Disease designations. This designation aims to expedite the development and review of SAT-3247, which is cu

Tone
Positive 95/100
Event
Market update
Published
02 Jul 2026 08:12
Source
GlobeNewswire
The Globe and Mail Direct company coverage

Stocks in play: Satellos Bioscience Inc.

Satellos Bioscience Inc. (T.MSCL) received Fast Track designation from the U.S. FDA for SAT-3247, its treatment for Duchenne. Following this announcement, the company's shares were trading up $1.09 at $11.29. This indicates positive market reaction to the regulatory development.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
30 Jun 2026 03:39
Source
The Globe and Mail
grafa.com Direct company coverage

Satellos gets FDA Fast Track for SAT-3247

Satellos Bioscience (NASDAQ:MSLE) has received FDA Fast Track designation for its drug SAT-3247, intended for the treatment of Duchenne muscular dystrophy. This designation aims to accelerate the development and regulatory review process for the drug, which already holds Orphan D

Tone
Positive 74/100
Event
Regulatory and legal
Published
29 Jun 2026 17:40
Source
grafa.com
Moomoo Direct company coverage

Satellos Bioscience Shares Climb After FDA Fast Track Designation

Satellos Bioscience Inc. recently received Fast Track Designation from the FDA for their drug candidate SAT-3257, which aims to treat Duchenne Muscular Dystrophy. This designation is intended to expedite the development and review of drugs for serious conditions with unmet medica

Tone
Positive 75/100
Event
Market update
Published
29 Jun 2026 15:09
Source
Moomoo
Baystreet.ca Direct company coverage

Satellos Bioscience Inc.

Satellos Bioscience Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug candidate, SAT-3247, for the treatment of Duchenne muscular dystrophy. Following this news, the company's shares (T.MSCL) were trading up $1.09 at $1

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 14:40
Source
Baystreet.ca
Stock Titan Direct company coverage

FDA Fast Track boosts Satellos (NASDAQ: MSLE) SAT-3247 Duchenne program

Satellos Bioscience Inc. announced its oral small-molecule drug candidate, SAT-3247, has received FDA Fast Track designation for Duchenne muscular dystrophy. This designation, along with existing Orphan Drug and Rare Pediatric Disease designations, is expected to expedite the dev

Tone
Positive 73/100
Event
Market update
Published
29 Jun 2026 10:40
Source
Stock Titan
Stock Titan Direct company coverage

Satellos wins FDA Fast Track for Duchenne drug SAT-3247

Satellos Bioscience Inc. announced that the FDA has granted Fast Track designation to its drug candidate SAT-3247 for the treatment of Duchenne muscular dystrophy. This designation, along with existing Orphan Drug and Rare Pediatric Disease designations, aims to expedite the deve

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 10:40
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBIT forward of Satellos Bioscience Inc – FWB:0IT

This article briefly presents the "Enterprise value to EBIT forward" metric for Satellos Bioscience Inc, traded on the Frankfurt Stock Exchange under the symbol FWB:0IT. The content indicates that the market for this stock was closed with no trades recorded at the time of the dat

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 17:10
Source
TradingView